Intra-Cellular Therapies Inc. (ITCI): Price and Financial Metrics

Intra-Cellular Therapies Inc. (ITCI): $42.45

-1.11 (-2.55%)

POWR Rating

Component Grades













Add ITCI to Watchlist
Sign Up

Industry: Biotech


of 476

in industry


  • ITCI scores best on the Value dimension, with a Value rank ahead of 51.42% of US stocks.
  • The strongest trend for ITCI is in Momentum, which has been heading down over the past 52 weeks.
  • ITCI's current lowest rank is in the Momentum metric (where it is better than 8.84% of US stocks).

ITCI Stock Summary

  • ITCI's price/sales ratio is 50.27; that's higher than the P/S ratio of 95.33% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for Intra-Cellular Therapies Inc; that's greater than it is for merely 9.04% of US stocks.
  • Revenue growth over the past 12 months for Intra-Cellular Therapies Inc comes in at 577.46%, a number that bests 98.55% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ITCI, based on their financial statements, market capitalization, and price volatility, are BIOC, MSGE, CNTG, CYRX, and SRAX.
  • Visit ITCI's SEC page to see the company's official filings. To visit the company's web site, go to

ITCI Valuation Summary

  • ITCI's price/earnings ratio is -11.4; this is 131.23% lower than that of the median Healthcare stock.
  • Over the past 93 months, ITCI's price/earnings ratio has gone up 10363.6.
  • Over the past 93 months, ITCI's EV/EBIT ratio has gone up 8923.4.

Below are key valuation metrics over time for ITCI.

Stock Date P/S P/B P/E EV/EBIT
ITCI 2021-08-31 48.4 4.9 -11.4 -11.0
ITCI 2021-08-30 47.2 4.8 -11.1 -10.7
ITCI 2021-08-27 45.9 4.6 -10.8 -10.4
ITCI 2021-08-26 45.4 4.6 -10.7 -10.3
ITCI 2021-08-25 46.8 4.7 -11.0 -10.6
ITCI 2021-08-24 46.4 4.7 -10.9 -10.5

ITCI Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at -44.94%.
  • The 5 year net cashflow from operations growth rate now stands at -40.38%.
  • Its year over year cash and equivalents growth rate is now at -27.41%.
ITCI's revenue has moved up $55,656,390 over the prior 67 months.

The table below shows ITCI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 55.74775 -238.914 -237.3665
2021-03-31 37.60783 -226.6136 -232.335
2020-12-31 22.81298 -230.0728 -227.0057
2020-09-30 10.41932 -196.886 -206.8893
2020-06-30 3.050728 -163.2962 -186.5681
2020-03-31 1.144092 -143.5801 -160.297

ITCI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks.
  • ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks.
  • BHVN, OCX, and BTX are the stocks whose asset turnover ratios are most correlated with ITCI.

The table below shows ITCI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.080 0.907 -0.448
2021-03-31 0.058 0.913 -0.480
2020-12-31 0.038 0.917 -0.536
2020-09-30 0.021 0.928 -0.703
2020-06-30 0.008 0.935 -0.843
2020-03-31 0.003 0.939 -0.803

ITCI Price Target

For more insight on analysts targets of ITCI, see our ITCI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.44 Average Broker Recommendation 1.27 (Strong Buy)

ITCI Stock Price Chart Interactive Chart >

Price chart for ITCI

ITCI Price/Volume Stats

Current price $42.45 52-week high $47.03
Prev. close $43.56 52-week low $23.38
Day low $41.26 Volume 355,500
Day high $43.78 Avg. volume 514,843
50-day MA $40.64 Dividend yield N/A
200-day MA $36.92 Market Cap 3.46B

Intra-Cellular Therapies Inc. (ITCI) Company Bio

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company was founded in 2002 and is based in New York, New York.

ITCI Latest News Stream

Event/Time News Detail
Loading, please wait...

ITCI Latest Social Stream

Loading social stream, please wait...

View Full ITCI Social Stream

Latest ITCI News From Around the Web

Below are the latest news stories about Intra-Cellular Therapies Inc that investors may wish to consider to help them evaluate ITCI as an investment opportunity.

Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript

Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Senior Vice President and Chief Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer. As a reminder, during today's call, we will be making certain forward-looking statements.

Yahoo | November 9, 2021

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2021

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Bipolar depression launch preparations are progressing well; sales force expansion is substantially complete. Total revenues were $22.2 million for the third quarter of 2021, compared to $7.4 million for the same period in the prior year, representing an increase of approximately 200%. CAPLYTA achieved net product revenues o

Yahoo | November 9, 2021

Nuveen Asset Management LLC Sells 67,000 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Nuveen Asset Management LLC lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 8.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 694,758 shares of the biopharmaceutical companys stock after selling 67,000 shares during the period. Nuveen Asset Management LLCs holdings in []

Dakota Financial News | November 5, 2021

Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 9, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2021. To access

Yahoo | November 2, 2021

Read More 'ITCI' Stories Here

ITCI Price Returns

1-mo -4.15%
3-mo 35.06%
6-mo N/A
1-year 69.94%
3-year 174.40%
5-year 217.98%
YTD 33.49%
2020 -7.32%
2019 201.23%
2018 -21.34%
2017 -4.04%
2016 -71.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.713 seconds.